Clinical Research

 
Stock Quotes for Clinical Research top ^
  • Industry: Business Services
  • Sector: Industrials
Sign-up for vmcs investment picks

 
News Articles for Clinical Research top ^
VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its clinical programs were presented at the 17 th Annual Meeting of the American Society of Gene and Cell Therapy, which is taking place in in Washington, DC, May 21 to 24.
Sign-up for Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs investment picks
Clinic Will Feature State-of-the-Art Digital Technology and Enhance Access to Oral Health Care for the Underserved MELVILLE, N.Y. , May 14, 2014 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC) , the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, in partnership with Meharry Medical College School of Dentistry, announced today the unveiling and dedication of the Henry Schein Cares Graduate Programs Residency Clinic.
Sign-up for Henry Schein Announces The Unveiling And Dedication Of The Henry Schein Cares Graduate Programs Residency Clinic At Meharry Medical College School Of Dentistry investment picks
SAN DIEGO , May 14, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) , a developer of cell-free molecular diagnostics, today announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). An additional abstract, submitted by Filip Janku , M.D., Ph.D., of The University of Texas MD Anderson Cancer, has been accepted for publication in 2014 ASCO Annual Meeting Proceedings , a Journal of Clinical Oncology.
Sign-up for Trovagene Announces Data Presentations, Published Abstracts at Annual Meeting of American Society of Clinical Oncology investment picks
ROCKVILLE, Md., April 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will present pre-clinical data on its novel DART® candidate for the treatment of autoimmune disorders, MGD010, at IMMUNOLOGY 2014, the American Association of Immunologists Annual Meeting, in Pittsburgh, PA.
Sign-up for MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014 investment picks
RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers In light of the positive results, and subject to regulatory requirements, the Company plans to submit, during the third quarter of this year, a European marketing application for RHB-102 for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients RHB-102 is a proprietary, once-daily, extended release oral pill formulation of the anti-emetic oncology support drug ondansetron RedHill is also pursuing a new undisclosed indication for RHB-102, which may significantly expand its potential market, with a Phase III study planned to commence in the U.S. later this year TEL-AVIV, Israel, April 30, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
Sign-up for RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014 investment picks
ROCKVILLE, Md., May 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data on MGD010, a bi-specific Dual-Affinity Re-targeting (DART®) protein, demonstrating its ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders.
Sign-up for MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014 investment picks
SAN DIEGO , May 5, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP) , an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin ® (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers.
Sign-up for MEI Pharma Initiates Clinical Study Of Mitochondrial Inhibitor Drug Candidate ME-344 In Small Cell Lung And Ovarian Cancers investment picks
NORTHBROOK, Ill., May 14, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH) , a company enhancing medicine through targeted molecular diagnostics, today announced that six studies performed by various U.S. and international medical facilities have been presented at the 24 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) this week.
Sign-up for Studies Presented at ECCMID 2014 Highlight Accuracy and Potential Clinical Utility of Several Nanosphere Infectious Disease Tests investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1115678&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Threshold Announces Clinical Data on TH-302 in Glioblastoma and Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2014 investment picks
2014/5/23
SHANGHAI , May 23, 2014 /PRNewswire/ -- Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE:WX) , a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States , today announced a strategic biomarker collaboration.
Sign-up for Targos Molecular Pathology GmbH and WuXi PharmaTech to Collaborate in Clinical Biomarker Services and Pathology Training in China investment picks
Clinical collaboration with CVS/pharmacy and MinuteClinic will increase access to care and help improve medication adherence for patients WOONSOCKET, R.I. , May 15, 2014 /PRNewswire/ -- CVS Caremark (NYSE: CVS) announced today it has entered into new clinical affiliations with four major regional health systems to enhance access to high-quality, affordable health care services for patients.
Sign-up for CVS Caremark Announces New Clinical Affiliations with Four Major Regional Health Systems investment picks
Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection SAN DIEGO , May 20, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) , a developer of cell-free molecular diagnostics, today announced that data published from ongoing clinical validation studies demonstrate that the company's precision cancer monitoring technology is suitable to non-invasively determine oncogene mutation status in patients with malignant disease.
Sign-up for Trovagene Announces Publication of Data from Clinical Validation Program Using Its Precision Cancer Monitoring Platform investment picks
Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas , May 8, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) , a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2014.
Sign-up for Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2014 First Quarter Financial Results investment picks
2014/5/12
ROCKVILLE, Md.
Sign-up for Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update investment picks
HAMPTON, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago.
Sign-up for Celldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014 investment picks
PORTLAND, Ore., May 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that data from the Company's Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50 th Annual Meeting.
Sign-up for Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting investment picks
BERKELEY HEIGHTS, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines.
Sign-up for Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML investment picks
ANN ARBOR, Mich., April 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the independent Data and Safety Monitoring Board (DSMB) for the company's ixCELL-DCM Phase 2b clinical trial has recommended continuing the study without modification as planned following an interim review of unblinded safety data from the trial.
Sign-up for Aastrom Reports Data and Safety Monitoring Board Recommendation to Continue ixCELL-DCM Clinical Trial investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Clinical Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Client Companies  |  Next: Clinical Research Study